Innoviva, Inc. (INVA) wird mit einem nachlaufenden KGV von gehandelt 6.5, erwartetes KGV von 12.5. Die nachlaufende Gewinnrendite beträgt 15.34%, erwartete Gewinnrendite 8.00%. PEG 0.01 (Peter Lynch unterbewertet ≤1,0). Die Graham-Zahl beträgt $35.76.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 86/100 mit 6/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 19.8 | -0.05 | -3.34 | 8.83 | 0.08% |
| 2017 | 11.3 | 0.09 | -6.25 | 6.99 | 0.02% |
| 2018 | 4.5 | 0.02 | 11.46 | 6.74 | 0.00% |
| 2019 | 9.1 | -0.15 | 4.57 | 5.49 | 0.00% |
| 2020 | 5.6 | 0.13 | 2.33 | 3.73 | - |
| 2021 | 5.3 | 0.11 | 3.41 | 3.61 | - |
| 2022 | 4.3 | -0.82 | 1.63 | 2.79 | - |
| 2023 | 5.8 | -1.20 | 1.56 | 3.38 | - |
| 2024 | 46.5 | -0.53 | 1.57 | 3.03 | - |
| 2025 | 5.0 | 0.01 | 1.15 | 3.17 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $0.53 | $133.57M | $59.54M | 44.6% |
| 2017 | $1.17 | $217.22M | $134.14M | 61.8% |
| 2018 | $3.48 | $261M | $395.06M | 151.4% |
| 2019 | $1.43 | $261.02M | $157.29M | 60.3% |
| 2020 | $2.02 | $336.79M | $224.4M | 66.6% |
| 2021 | $2.87 | $391.87M | $368.84M | 94.1% |
| 2022 | $2.37 | $331.34M | $213.92M | 64.6% |
| 2023 | $2.20 | $310.46M | $179.72M | 57.9% |
| 2024 | $0.36 | $358.71M | $23.39M | 6.5% |
| 2025 | $3.30 | $425.13M | $271.17M | 63.8% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $1.91 | $1.84 – $2.02 | $439.36M | $431.39M – $447.34M | 2 |
| 2027 | $2.21 | $2.07 – $2.34 | $495M | $487.41M – $502.58M | 2 |
| 2028 | $2.00 | $1.62 – $2.38 | $543.05M | $527.56M – $558.54M | 2 |
| 2029 | $2.72 | $2.48 – $2.91 | $607.94M | $568.17M – $641.91M | 1 |
| 2030 | $1.84 | $1.68 – $1.97 | $654.34M | $611.53M – $690.9M | 1 |
